This study investigated voriconazole (VRC) unbound plasma concentration and its
relationship with adverse drug reactions (ADRs) in patients with malignant hematologic …

The pharmacokinetics of voriconazole shows large intra-individual and inter-individual
variability and is affected by various factors. Recently, inflammation has been focused as a …

Voriconazole (VRC) overdoses are frequent and expose patients at high risk of adverse
effects. This case–control study performed in hematological patients who benefited from …

Voriconazole (VRC) is a second-generation triazole licensed to treat patients with invasive
aspergillosis, invasive candiadiasis caused by Candida species with reduced susceptibility …

Voriconazole (VRC), a triazole agent is extensively metabolized by CYP2C19, CYP2C9, and
to a lesser extent, by CYP3A4. Few data are available regarding disposition of the main …

Background Voriconazole concentrations display a large variability, which cannot
completely be explained by known factors. We investigated the relationships of voriconazole …

Plasma protein binding (PPB) can possibly alter the already variable pharmacokinetics of
voriconazole. Voriconazole PPB was determined only once, being 58%, according to …

Aims: To explore the interactive influence of glucocorticoids and cytochrome P450 (CYP450)
polymorphisms on voriconazole (VRC) plasma trough concentrations (Cmin) and provide a …

Voriconazole is a broad-spectrum triazole antifungal agent. A number of studies have
revealed that the impact of C-reactive protein (CRP) on voriconazole pharmacokinetics was …

The aim of this study was to identify potential factors associated with insufficient/toxic
voriconazole trough concentrations (VTCs) in patients in order to screen the high-risk …